BioSimulytics
PrivateLast Round
Seed
Jan 21, 2025
Total Funding Raised
$3.46M
Company Overview
BioSimulytics operates in Healthcare & Life Sciences and is based in Dublin. Its latest recorded funding round was a Grant round in June 2023.
BioSimulytics is a biotechnology company that provides an AI-enhanced predictive platform for crystal structure prediction to assist pharmaceutical companies in drug development.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BioSimulytics Comparables
Compare BioSimulytics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| XtalPi | 79% | |
| Avant-garde Materials Simulation | 78% | |
| Cadence Design Systems | 75% |
For institutional investors. Book with your work email.
BioSimulytics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Jan 21, 2025 | ||||
| Grant | Jun 20, 2023 | ||||
| Seed | Sep 2, 2021 | ||||
| Accelerator | Nov 28, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BioSimulytics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant |
| European Investment Bank Group | Seed |
| University College Dublin | Accelerator |
| Enterprise Ireland | Seed, Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 20, 2023
Secured $2.7M from the European Innovation Council Fund.
- Sep 2, 2021
$702K raised with Enterprise Ireland participating.
For institutional investors. Book with your work email.
BioSimulytics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BioSimulytics's valuation, stock price, and market status.
Is BioSimulytics a public or private company?
BioSimulytics is a private company.
What is the current stock price of BioSimulytics?
BioSimulytics is a private company, so its shares have no public market price. Caplight tracks BioSimulytics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BioSimulytics worth (valuation)?
Valuation information for BioSimulytics is not publicly available.
Can I buy BioSimulytics stock?
BioSimulytics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BioSimulytics's last funding round?
BioSimulytics's most recent funding round was Seed on January 21, 2025.
Who are the main investors in BioSimulytics?
Key investors in BioSimulytics include European Innovation Council Fund, European Investment Bank Group, University College Dublin, Enterprise Ireland.
Will BioSimulytics IPO soon?
No public IPO plans have been announced for BioSimulytics.
How can I track BioSimulytics secondary market activity?
Caplight tracks bids, offers, and trades in BioSimulytics's shares on secondary markets.